Cited 0 times in
만성 B형 간질환 환자에서 라미부딘 장기투여의 치료효과
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 백용한 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2020-01-23T05:13:14Z | - |
dc.date.available | 2020-01-23T05:13:14Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 1738-222X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174098 | - |
dc.description.abstract | Background/Aims : We studied to evaluate the virological and biochemical responses to lamivudine and to detect YMDD mutants in patients who received long-term lamivudine therapy. Method : We conducted a one-year trial of lamivudine in 45 Korean patients with chronic liver disease due to hepatitis B virus. The patients were treated with a single oral average dose of 100 mg of lamivudine every day for 12 months. Results : The suppression of serum HBV DNA was sustained in 77.8% of the patients and the normalization of serum ALT in 80%. The proportions of patients with HBeAg seroconversion were 25%. YMDD mutants were detected in 4 of 8 patients who showed sustained HBV DNA and serum ALT response (n=31) and in 3 of 8 patients who showed HBV DNA or serum ALT breakthrough (n=9). The response to lamivudine therapy in HBeAg-negative patients was excellent. Conclusion : Lamivudine therapy resulted in a significant virological and biochemical improvements and were well tolerated. But, YMDD mutants were detected during lamivudine therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | Korean Journal of Hepatology (대한간학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 만성 B형 간질환 환자에서 라미부딘 장기투여의 치료효과 | - |
dc.title.alternative | The Effect of Long-term Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 한광협 | - |
dc.contributor.googleauthor | 김진석 | - |
dc.contributor.googleauthor | 정효영 | - |
dc.contributor.googleauthor | 안상훈 | - |
dc.contributor.googleauthor | 백용한 | - |
dc.contributor.googleauthor | 이관식 | - |
dc.contributor.googleauthor | 전재윤 | - |
dc.contributor.googleauthor | 문영명 | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J02036 | - |
dc.identifier.eissn | 2093-8047 | - |
dc.subject.keyword | Lamivudine | - |
dc.subject.keyword | HBV DNA breakthrough | - |
dc.subject.keyword | ALT breakthrough | - |
dc.subject.keyword | HBeAg seroconversion | - |
dc.subject.keyword | YMDD mutant | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | 백용한 | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.contributor.affiliatedAuthor | 전재윤 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 5 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 97 | - |
dc.citation.endPage | 104 | - |
dc.identifier.bibliographicCitation | Korean Journal of Hepatology (대한간학회지), Vol.5(2) : 97-104, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.